[1]李海志,李 特,胡晓倩,等.基因检测指导难治性高血压用药有效性及安全性的系统评价[J].医学信息,2023,36(19):34-39.[doi:10.3969/j.issn.1006-1959.2023.19.008]
　LI Hai-zhi,LI Te,HU Xiao-qian,et al.Systematic Evaluation of the Efficacy and Safety of Gene Detection in Guiding the Treatment of Refractory Hypertension[J].Journal of Medical Information,2023,36(19):34-39.[doi:10.3969/j.issn.1006-1959.2023.19.008]
点击复制

基因检测指导难治性高血压用药有效性及安全性的系统评价()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年19期
页码:
34-39
栏目:
医学数据科学
出版日期:
2023-10-01

文章信息/Info

Title:
Systematic Evaluation of the Efficacy and Safety of Gene Detection in Guiding the Treatment of Refractory Hypertension
文章编号:
1006-1959（2023）19-0034-06
作者:
李海志; 李 特; 胡晓倩; 等
（1.云南省阜外心血管病医院药剂科，云南 昆明 650000；2.云南经济管理学院医学院，云南 昆明 650000）
Author(s):
LI Hai-zhi; LI Te; HU Xiao-qian; et al.
(1.Department of Pharmacy,Fuwai Yunnan Cardiovascular Hospital,Kunming 650000,Yunnan,China;2.Medical School of Yunnan University of Bussiness Management,Kunming 650000,Yunnan,China)
关键词:
基因检测; 难治性高血压; 有效性; 系统评价; 随机对照试验
Keywords:
Gene detection; Refractory hypertension; Effectiveness; System evaluation; Randomized controlled trial
分类号:
R544.1
DOI:
10.3969/j.issn.1006-1959.2023.19.008
文献标志码:
A
摘要:
目的 系统评价基因检测指导难治性高血压的用药有效性及安全性，为临床治疗难治性高血压用药提供新的用药参考。方法 检索万方数据库、维普中文期刊数据库、中国知网、PubMed、EMbase、Medline、Cochrane图书馆和中国生物医学文献数据库（CBM），收集使用基因指导用药组（研究组）和常规用药组（对照组）难治性高血压的随机对照试验（RCT），检索时限为从建库之日起至2022年8月。在筛选文献，提取资料后，使用RevMan5.3软件对收缩压、舒张压、总有效率以及不良反应发生率进行荟萃分析，比较研究组和对照组在有效性及安全性方面的差异。结果 共纳入24篇符合研究的文献，共计4888例患者，研究组2617例，对照组2271例，其中有3篇提到了基因检测指导难治性高血压的总有效率，有6篇提到了不良反应发生率。Meta分析结果显示，研究组收缩压和舒张压降压效果均优于对照组，差异有统计学意义[MD=-10.40，95%CI（-14.67，-6.14），P＜0.000 01；MD=-4.32，95%CI（-7.26，-1.38），P=0.004]；研究组总有效率高于对照组，差异有统计学意义[RD=0.12，95%CI（0.03，0.21），P=0.01]；研究组不良反应发生率低于对照组，差异有统计学意义[OR=0.28，95%CI（0.18，0.46），P＜0.000 01]。结论 基因指导难治性高血压用药的疗效优于常规用药，不良反应发生率低于常规用药，因此基因检测指导可用于难治性高血压用药的临床治疗中。
Abstract:
Objective To systematically evaluate the efficacy and safety of gene detection in guiding the treatment of refractory hypertension, and to provide a new reference for clinical treatment of refractory hypertension.Methods Wanfang database, VIP Chinese journal database, China National Knowledge Infrastructure (CNKI), PubMed, EMbase, Medline, Cochrane Library and Chinese BioMedical Literature Database (CBM) were searched to collect randomized controlled trials (RCTs) of refractory hypertension in the gene-guided medication group (study group) and the conventional medication group (control group). The retrieval time was from the date of database establishment to August 2022. After screening the literature and extracting the data, RevMan5.3 software was used to conduct a meta-analysis of systolic blood pressure, diastolic blood pressure, total effective rate and incidence of adverse reactions, and to compare the differences in efficacy and safety between the study group and the control group.Results A total of 24 articles were included in the study, with a total of 4888 patients, 2617 patients in the study group and 2271 patients in the control group. Among them, 3 articles mentioned the total effective rate of genetic testing to guide refractory hypertension, and 6 articles mentioned the incidence of adverse reactions. The results of Meta-analysis showed that the antihypertensive effect of systolic blood pressure and diastolic blood pressure in the study group was better than that in the control group, and the difference was statistically significant [MD=-10.40, 95%CI(-14.67,-6.14),P<0.000 01; MD=-4.32, 95%CI(-7.26,-1.38),P=0.004]; the total effective rate of the study group was higher than that of the control group, and the difference was statistically significant [RD=0.12,95%CI(0.03,0.21),P=0.01]; the incidence of adverse reactions in the study group was lower than that in the control group, and the difference was statistically significant [OR=0.28,95%CI(0.18,0.46),P<0.000 01].Conclusion The efficacy of gene-guided medication for refractory hypertension is better than that of conventional medication, and the incidence of adverse reactions is lower than that of conventional medication. Therefore, gene detection guidance can be used in the clinical treatment of refractory hypertension.

参考文献/References:

[1]Carey RM,Calhoun DA,Bakris GL,et al.Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association[J].Hypertension,2018,72(5):e53-e90.[2]Cunningham P,Chapman A.The future of pharmacogenetics in the treatment of hypertension.[J].Pharmacogenomics,2019,20(3):129-132.[3]李建民,张景昌,黄学成,等.基因多态性与高血压药物疗效的相关性研究[J].巴楚医学,2022,5(2):33-37.[4]陈伟杰,李恒,王善花,等.贝那普利基因导向治疗与常规治疗高血压病的疗效及安全性比较[J].岭南急诊医学杂志,2020,25(1):51-54.[5]肖智林,楚志文,杨梅,等.药物基因组学导向高血压个体化用药的临床研究[J].中国实用内科杂志,2020,40(10):850-854.[6]王瑞,秦超师,刘静,等.基因指导降压药物选择与传统用药疗效比较[J].心脏杂志,2021,33(2):133-137.[7]孙晓燕,周丽娟,吕朋举,等.河南汉族人群抗高血压药物相关基因多态性与高血压发病及降压效果的关联研究[J].中国医院药学杂志,2021,41(17):1730-1735.[8]董天崴,王爽,王立波,等.比索洛尔按基因导向治疗高血压的疗效[J].心血管康复医学杂志,2014,23(5):523-526.[9]秦丽.药物基因检测在唐山市区原发性高血压患者治疗中的安全性及有效性分析[D].唐山:华北理工大学,2022.[10]袁梅.药物基因检测在我院高血压患者中的应用效果[J].医学理论与实践,2021,34(1):10-12.[11]李智,孙伟.基因导向美托洛尔个体化治疗与常规治疗高血压的临床疗效、安全性及经济性评价[J].中国药物经济学,2017,12(8):27-29,33.[12]何艳,余报,黄家贵,等.高血压基因导向个体化用药的临床研究[J].中华临床医师杂志(电子版),2018,12(12):679-683.[13]倪小丽,汤权琪,邹仕贵,等.基因检测指导下的个体化用药在农村高血压患者管理中的效果评价[J].中华疾病控制杂志,2019,23(10):1284-1288.[14]高菊英,刘丽宏,万子睿,等.抗高血压药物基因多态性对呼伦贝尔地区三少民族高血压患者个体化治疗方案的参考价值[J].中国药物应用与监测,2022,19(3):145-149.[15]乔崇.南阳地区高血压人群药物基因组学与抗高血压基因导向个体化用药临床研究[D].新乡:新乡医学院,2014.[16]张峰,杨军,魏晓冬,等.CYP2D6*10基因多态性与美托洛尔基因导向治疗对高血压患者左室重构影响的研究[J].黑龙江医药科学,2014,37(1):108-109.[17]彭鹏,董天崴,高雨田,等.ACE基因导向治疗对高血压及颈动脉内膜中层厚度的影响[J].中国老年学杂志,2015(10):2665-2666,2667.[18]唐杨玲,董天崴,王爽,等.CYP3A5基因多态性与高血压个体化精准治疗的相关性研究[J].微量元素与健康研究,2019,36(1):14-17.[19]高英英,高琴,徐珊珊,等.β受体阻滞剂精准干预交感神经兴奋性在高血压患者中的临床应用[J].中华高血压杂志,2019,27(11):1065-1069.[20]杜娜娜,赵美丽.药物基因组学指导下个体化用药对高血压患者依从性研究[J].甘肃科技,2020,36(3):109-111.[21]Dhameja K,Singh S,Mustafa MD,et al.Therapeutic effect of yoga in patients with hypertension with reference to GST gene polymorphism[J].J Altern Complement Med,2013,19(3):243-249. [22]Fan X,Wang Y,Sun K,et al.Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women[J].Clin Pharmacol Ther,2007,82(2):187-196. [23]He H,Li LM,Cao WH,et al.A study of the relationships between angiotensin- converting enzyme gene, chymase gene polymorphisms, pharmacological treatment with ACE inhibitor and regression of left ventricular hypertrophy in essential hypertension patients treated with benazepril[J].Ann Hum Biol,2005,32(1):30-43.[24]Hernández D,Lacalzada J,Salido E,et al.Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism[J].Kidney Int,2000,58(2):889-897.[25]Gong HT,Ma XL,Chen BX,et al.Polymorphisms of the angiotensin II type 1 receptor gene affect antihypertensive response to angiotensin receptor blockers in hypertensive Chinese[J].Genet Mol Res,2013,12(2):2068-2075.[26]Redon J,Luque-Otero M,Martell N,et al.POLPRI Investigators. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients[J].Pharmacogenomics J,2005,5(1):14-20.

相似文献/References:

[1]蒋罗兰,蒋新华.基于Web of Science核心合集的难治性高血压研究可视化分析[J].医学信息,2023,36(15):30.[doi:10.3969/j.issn.1006-1959.2023.15.006]
　JIANG Luo-lan,JIANG Xin-hua.Visualization Analysis of Resistant Hypertension Based on Web of Science Core Collection[J].Journal of Medical Information,2023,36(19):30.[doi:10.3969/j.issn.1006-1959.2023.15.006]

更新日期/Last Update: 1900-01-01